TherapeuticsMD, Inc. (TXMD)
NASDAQ$0.7252
Market Cap
$8.36M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
391 of 924
Rank in Industry
20 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
TXMD Insider Trading Activity
TXMD Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $9,138 | 2 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Collins Cooper C. | director | 2 | $9,138 | 0 | $0 | $9,138 |
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and …
Insider Activity of TherapeuticsMD, Inc.
Over the last 12 months, insiders at TherapeuticsMD, Inc. have bought $9,138 and sold $0 worth of TherapeuticsMD, Inc. stock.
On average, over the past 5 years, insiders at TherapeuticsMD, Inc. have bought $7.08M and sold $13.02M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Collins Cooper C. (director) — $9,138.
The last purchase of 4,094 shares for transaction amount of $7,099 was made by Collins Cooper C. (director) on 2024‑08‑22.
List of Insider Buy and Sell Transactions, TherapeuticsMD, Inc.
| 2024-08-22 | Collins Cooper C. | director | 4,094 0.0352% | $1.73 | $7,099 | -23.43% | ||
| 2024-08-21 | Collins Cooper C. | director | 1,200 0.0105% | $1.70 | $2,039 | -20.41% | ||
| 2023-12-07 | Sale | Walker Marlan D | Chief Executive Officer | 4,550 0.0421% | $2.24 | $10,187 | -14.48% | |
| 2023-12-06 | Sale | Walker Marlan D | Chief Executive Officer | 14,500 0.1412% | $2.31 | $33,496 | -16.00% | |
| 2023-04-26 | Sale | Walker Marlan D | Chief Executive Officer | 692 0.0079% | $3.64 | $2,518 | -25.78% | |
| 2023-04-12 | Sale | Walker Marlan D | Chief Executive Officer | 1,170 0.013% | $3.65 | $4,276 | -23.14% | |
| 2023-01-27 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 49 0.0005% | $5.09 | $249 | -30.90% | |
| 2023-01-26 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 1,648 0.0183% | $5.08 | $8,371 | -27.36% | |
| 2023-01-24 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 7 <0.0001% | $5.31 | $37 | -29.39% | |
| 2023-01-23 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 1,302 0.0145% | $5.34 | $6,950 | -30.45% | |
| 2022-12-30 | Sale | Rubric Capital Management LP | director | 29,000 – | $1,333.00 | $38.66M | -31.75% | |
| 2022-12-09 | Sale | Bernick Brian | Co-Chief Executive Officer | 320 0.0035% | $6.31 | $2,020 | -39.64% | |
| 2022-12-09 | Rubric Capital Management LP | director | 14,825 0.1558% | $6.09 | $90,284 | -39.64% | ||
| 2022-12-08 | Rubric Capital Management LP | director | 300 0.0032% | $5.83 | $1,749 | -35.12% | ||
| 2022-12-07 | Sale | Naughton Gail K | director | 3,922 0.038% | $5.26 | $20,635 | -35.44% | |
| 2022-12-07 | Rubric Capital Management LP | director | 20,113 0.2099% | $5.66 | $113,890 | -35.44% | ||
| 2022-12-06 | Sale | Walker Marlan D | General Counsel | 1,048 0.0106% | $4.95 | $5,185 | -27.96% | |
| 2022-12-06 | Sale | Donegan Michael C | Interim CFO/CAO/VP of Finance | 910 0.0089% | $4.78 | $4,345 | -27.96% | |
| 2022-12-06 | Sale | Bernick Brian | Co-Chief Executive Officer | 935 0.0094% | $4.92 | $4,602 | -27.96% | |
| 2022-12-06 | Sale | Glickman Mark A | Co-Chief Executive Officer | 440 0.0044% | $4.92 | $2,165 | -27.96% |
Total: 197
*Gray background shows transactions not older than one year
*Some uncertain data for Preferred Stock share type transactions are shown in italics; for actual data please follow the link
Insider Historical Profitability
<0.0001%
| Collins Cooper C. | director | 52016 0.451% | $37,722.00 | 9 | 1 | <0.0001% |
| Finizio Robert G | CEO | 17991637 156.0095% | $13.05M | 5 | 24 | <0.0001% |
| Milligan John C.K. IV | Secretary/CEO of subsidiary | 1752703 15.1981% | $1.27M | 3 | 24 | <0.0001% |
| Thompson Tommy G | director | 715600 6.2051% | $518,953.12 | 13 | 0 | +1.19% |
| C.S. Finance LLC | 357606 3.1009% | $259,335.87 | 1 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$2,051,022 | 1591 | -12.84% | $76.27M | |
$22,899,264 | 81 | 34.90% | $26.7M | |
$125,860,243 | 57 | -4.48% | $54.94M | |
$2,740,482 | 50 | 9.37% | $36.33M | |
TherapeuticsMD, Inc. (TXMD) | $30,209,812 | 45 | -1.91% | $8.36M |
TXMD Institutional Investors: Active Positions
| Increased Positions | 12 | +29.27% | 161,593 | +4.78% |
| Decreased Positions | 9 | -21.95% | 11,821 | -0.35% |
| New Positions | 8 | New | 158,352 | New |
| Sold Out Positions | 4 | Sold Out | 728 | Sold Out |
| Total Postitions | 44 | +7.32% | 4M | +4.43% |
TXMD Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Rubric Capital Management Lp | $1,109.00 | 9.94% | 1.19M | 0 | 0% | 2024-12-31 |
| Clearline Capital Lp | $591.00 | 5.29% | 635,222 | -1,400 | -0.22% | 2024-12-31 |
| Tejara Capital Ltd | $367.00 | 3.29% | 394,661 | -6,785 | -1.69% | 2024-12-31 |
| Vanguard Group Inc | $360.00 | 3.23% | 387,582 | 0 | 0% | 2024-12-31 |
| Adar1 Capital Management, Llc | $251.00 | 2.25% | 270,160 | 0 | 0% | 2024-12-31 |
| Citadel Advisors Llc | $136.00 | 1.22% | 145,802 | +145,802 | New | 2024-12-31 |
| Morgan Stanley | $123.00 | 1.1% | 132,389 | +670 | +0.51% | 2024-12-31 |
| Blackrock, Inc. | $108.00 | 0.97% | 116,132 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $101.00 | 0.9% | 108,333 | 0 | 0% | 2024-12-31 |
| Bridgeway Capital Management, Llc | $32.00 | 0.28% | 34,000 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.